MACS GMP PepTivator

The MACS GMP PepTivator EBV LMP2A is a peptide pool that consists mainly of 15-mer peptides with eleven amino-acid overlap. It has been developed for efficient
in vitro
stimulation and subsequent isolation EBV LMP2A-specific CD4
and CD8
T cells.


MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.

Background information

Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and carcinogenic potential. More than 90% of human adults are infected with EBV. In healthy individuals, EBV typically establishes a persistent latent infection, in which the virus can be detected in resting, non-proliferating peripheral B lymphocytes. Expression of the viral protein latent membrane protein 2A (LMP2A) maintains the latency phase.


T cells are essential for the control of the outgrowth of EBV-infected B cells and LMP2A is one of the immunogenic targets. In EBV-associated malignancies, such as nasopharyngeal carcinoma and Hodgkin’s lymphoma, LMP2A is one in a restricted number of expressed viral proteins
Adoptive transfer of LMP2A-specific T cells may be an effective tool for the treatment of EBV-associated malignancies
in vitro
stimulation of LMP2A-specific CD4
and CD8
T cells with MACS GMP PepTivator EBV LMP2A causes the production of the effector cytokine IFN-gamma. The secretion of IFN-gamma then permits the enrichment of LMP2A-specific effector/memory T cells with the use of the CliniMACS Cytokine Capture System (IFN-gamma).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
  • Selected references

    1. Williams and Crawford (2006) Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 107: 862-869
    2. Bollard et al. (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-45
  • Certificates

    Please follow this
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 1
stimulation of
CHF  3'495.00

Related products

6 products available | view all